{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:49:19Z","timestamp":1780526959118,"version":"3.54.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.heliyon.2024.e25734","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T11:49:32Z","timestamp":1706874572000},"page":"e25734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4840-0460","authenticated-orcid":false,"given":"Said","family":"Moshawih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qais","family":"Jarrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Alim","family":"Bahrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Fern","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Poh","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.heliyon.2024.e25734_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00014-21","article-title":"Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection","volume":"95","author":"Chen","year":"2021","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41533-022-00300-z","article-title":"The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19","volume":"32","author":"Kushner","year":"2022","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.heliyon.2024.e25734_bib3","series-title":"NHS MEDICAL DIRECTOR Novel Coronavirus Anti-inflammatory Medications","author":"Powis","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib4","series-title":"NSAIDs for Pain Control during the Peri-Operative Period of Hip Fracture Surgery: A Systematic Review","author":"Pommier","year":"2023"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40121-020-00363-w","article-title":"Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study","volume":"10","author":"Abu Esba","year":"2021","journal-title":"Infect. Dis. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25734_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/cts.12904","article-title":"Association between prescribed ibuprofen and severe COVID-19 infection: a nationwide register-based cohort study","volume":"13","author":"Kragholm","year":"2020","journal-title":"Clinical and Translational Science"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25734_bib7","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/jcm9082586","article-title":"Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19","volume":"9","author":"Bruce","year":"2020","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25734_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003308","article-title":"Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study","volume":"17","author":"Lund","year":"2020","journal-title":"PLoS Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25734_bib9","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S2665-9913(21)00104-1","article-title":"Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study","volume":"3","author":"Drake","year":"2021","journal-title":"The Lancet Rheumatology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25734_bib10","first-page":"288","article-title":"NSAIDs: a double edged sword in viral infections","volume":"9","author":"Gerges","year":"2022","journal-title":"International Journal of Medical Reviews"},{"key":"10.1016\/j.heliyon.2024.e25734_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104849","article-title":"NSAIDs in patients with viral infections, including Covid-19: victims or perpetrators?","volume":"157","author":"Capuano","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2024.e25734_bib12","series-title":"D S A D D A S D MEDICAL REVIEWS Mini Review NSAIDs: A Double Edged Sword in Viral Infections","author":"Thabet","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e25734_bib13","unstructured":"Fukunaga, K., et al., Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury. (0022-1767 (Print)).."},{"key":"10.1016\/j.heliyon.2024.e25734_bib14","unstructured":"Carey, M.A., et al., Contrasting Effects of Cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the Host Response to Influenza A Viral Infection. (0022-1767 (Print)).."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25734_bib15","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/jmv.26139","article-title":"Increasing host cellular receptor\u2014angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection","volume":"92","author":"Zhuang","year":"2020","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib16","doi-asserted-by":"crossref","first-page":"9606","DOI":"10.1038\/s41598-021-88313-5","article-title":"Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19","volume":"11","author":"Oh","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e25734_bib17","unstructured":"Saheb Sharif-Askari, N., et al., Effect of Common Medications on the Expression of SARS-CoV-2 Entry Receptors in Kidney Tissue. (1752-8062 (Electronic)).."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25734_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060696","article-title":"Analgesics induce alterations in the expression of SARS-CoV-2 entry and arachidonic-acid-metabolizing genes in the mouse lungs","volume":"15","author":"Khirfan","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12985-022-01813-2","article-title":"NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study","volume":"19","author":"Reese","year":"2022","journal-title":"Virol. J."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25734_bib20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood.V97.6.1742","article-title":"Selective inhibition of interleukin-4 gene expression in human T cells by aspirin","volume":"97","author":"Cianferoni","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25734_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JS9.0000000000000101","article-title":"Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19","volume":"109","author":"Nainu","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.heliyon.2024.e25734_bib22","doi-asserted-by":"crossref","unstructured":"Alfajaro, M.M., et al., Activation of COX-2\/PGE2 Promotes Sapovirus Replication via the Inhibition of Nitric Oxide Production. LID - 10.1128\/JVI.01656-16 [doi] LID - e01656-16. 2017(1098-5514 (Electronic))..","DOI":"10.1128\/JVI.01656-16"},{"key":"10.1016\/j.heliyon.2024.e25734_bib23","series-title":"NSAID Treatment Suppresses VSV Propagation in Mouse CNS","author":"Chen","year":"2000"},{"key":"10.1016\/j.heliyon.2024.e25734_bib24","series-title":"Contrasting Effects of Cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the Host Response to Influenza A Viral Infection","author":"Carey","year":"2005"},{"key":"10.1016\/j.heliyon.2024.e25734_bib25","series-title":"W.H.O. The Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Patients with COVID-19","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib26","series-title":"Possible Effects of Repeated Exposure to Ibuprofen and Acetaminophen on the Intestinal Immune Response in Young Infants","first-page":"1532","author":"Langhendries","year":"2016"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25734_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060786","article-title":"Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients","volume":"8","author":"Voiriot","year":"2019","journal-title":"J. Clin. Med."},{"issue":"7503","key":"10.1016\/j.heliyon.2024.e25734_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.heliyon.2024.e25734_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh5552","article-title":"Nonsteroidal anti-inflammatory drugs sensitize epithelial cells to Clostridioides difficile toxin\u2013mediated mitochondrial damage","volume":"9","author":"Soto Oca\u00f1a","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.heliyon.2024.e25734_bib30","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ejim.2017.03.004","article-title":"Bacterial infections and NSAIDs exposure? Seek septic complications","volume":"41","author":"Le Turnier","year":"2017","journal-title":"Eur. J. Intern. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25734_bib31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.therap.2020.05.003","article-title":"Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection","volume":"75","author":"Micallef","year":"2020","journal-title":"Therapies"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25734_bib32","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/cc7766","article-title":"A multicentre case-control study of nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock","volume":"13","author":"Legras","year":"2009","journal-title":"Crit. Care"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25734_bib33","article-title":"Antimicrobial properties on non-antibiotic drugs in the era of increased bacterial resistance","volume":"9","author":"Lagadinou","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25734_bib34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd.2018.210","article-title":"Trial watch: the clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors","author":"Tang","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e25734_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637504","article-title":"Cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer","volume":"11","author":"Pu","year":"2021","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25734_bib36","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.21873\/anticanres.12768","article-title":"Impact of COX2 inhibitor for regulation of PD-L1 expression in non-small cell lung cancer","volume":"38","author":"Shimizu","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.heliyon.2024.e25734_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648139","article-title":"Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives","volume":"11","author":"Yi","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/imm.13588","article-title":"CD8+ T cell exhaustion in anti\u2010tumour immunity: the new insights for cancer immunotherapy","volume":"168","author":"Huang","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.heliyon.2024.e25734_bib39","series-title":"Non-steroidal Anti-inflammatory Drugs, Tumour Immunity and Immunotherapy","author":"Hussain","year":"2012"},{"key":"10.1016\/j.heliyon.2024.e25734_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yjmcc.2020.05.007","article-title":"p38 MAPK inhibition: a promising therapeutic approach for COVID-19","volume":"144","author":"Grimes","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/ar-2002-75400","article-title":"NSAIDs inhibit p38 MAPK activation","volume":"4","author":"Smythe","year":"2002","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e25734_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105475","article-title":"Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier","volume":"209","author":"Faist","year":"2023","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25734_bib43","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/ptr.7902","article-title":"Therapeutic prospects of naturally occurring p38 MAPK inhibitors tanshinone IIA and pinocembrin for the treatment of SARS-CoV-2-induced CNS complications","volume":"37","author":"Valipour","year":"2023","journal-title":"Phytother Res."},{"key":"10.1016\/j.heliyon.2024.e25734_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.781352","article-title":"IL1\u03b2 promotes TMPRSS2 expression and SARS-CoV-2 cell entry through the p38 MAPK-GATA2 Axis","volume":"12","author":"Cioccarelli","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.631879","article-title":"SARS-CoV-2 switches \u2018on\u2019 MAPK and NF\u03baB signaling via the reduction of nuclear DUSP1 and DUSP5 expression","volume":"12","author":"Goel","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.aivir.2016.08.006","article-title":"Interaction of SARS and MERS coronaviruses with the antiviral interferon response","volume":"96","author":"Kindler","year":"2016","journal-title":"Adv. Virus Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25734_bib47","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1096\/fj.06-6589com","article-title":"Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways","volume":"21","author":"Liu","year":"2007","journal-title":"Faseb. J."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25734_bib48","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.biocel.2006.02.003","article-title":"Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT\/enhancer binding protein","volume":"38","author":"Yan","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib49","series-title":"Angiotensin-converting Enzyme 2 Is a Functional Receptor for the SARS Coronavirus","first-page":"1476","author":"Li","year":"2003"},{"key":"10.1016\/j.heliyon.2024.e25734_bib50","series-title":"The Race to Treat COVID-19: Potential Therapeutic Agents for the Prevention and Treatment of SARS-CoV-2","author":"Shagufta","year":"2021"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25734_bib51","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib52","series-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","author":"Hoffmann","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib53","author":"Hamidi","year":"2021","journal-title":"Role of pirfenidone in TGF-\u03b2 pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e25734_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01257-21","article-title":"The NF-\u03baB transcriptional footprint is essential for SARS-CoV-2 replication","volume":"95","author":"Nilsson-Payant","year":"2021","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41541-021-00391-8","article-title":"Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines","volume":"6","author":"Sartorius","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.heliyon.2024.e25734_bib56","series-title":"Single-cell RNA-Seq Data Analysis on the Receptor ACE2 Expression Reveals the Potential Risk of Different Human Organs Vulnerable to 2019-nCoV Infection","author":"Zou","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib57","series-title":"Enhanced Angiotensin II-Induced Cardiac and Aortic Remodeling in ACE2 Knockout Mice","author":"Alghamri","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e25734_bib58","series-title":"The Novel Angiotensin-Converting Enzyme (ACE) Homolog, ACE2, Is Selectively Expressed by Adult Leydig Cells of the Testis","author":"Douglas","year":"2004"},{"key":"10.1016\/j.heliyon.2024.e25734_bib59","first-page":"1758","volume":"vol. 2021","author":"Coto","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e25734_bib60","series-title":"Angiotensin-converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target","author":"Zhang","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib61","series-title":"Coronavirus Disease 2019 (COVID-19) and the Renin-Angiotensin System: A Closer Look at Angiotensin-Converting Enzyme 2 (ACE2)","author":"Zemlin","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib62","series-title":"COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children","author":"Ciaglia","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib63","series-title":"Effects of Nonsteroidal Anti-inflammatory Drugs on Serum Proinflammatory Cytokines in the Treatment of Ankylosing Spondylitis","author":"Yan","year":"2018"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e25734_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/v12101092","article-title":"Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: a comprehensive review","volume":"12","author":"Al-Horani","year":"2020","journal-title":"Viruses"},{"issue":"7821","key":"10.1016\/j.heliyon.2024.e25734_bib65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e25734_bib66","series-title":"The Role of Acidosis in the Pathogenesis of Severe Forms of COVID-19. LID - 10.3390\/biology10090852","author":"Nechipurenko","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e25734_bib67","article-title":"SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein","author":"Albornoz","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e25734_bib68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coi.2018.03.010","article-title":"Ion homeostasis and ion channels in NLRP3 inflammasome activation and regulation","volume":"52","author":"Hafner-Bratkovic","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib69","series-title":"Nonsteroid Anti-inflammatory Drugs Inhibit Both the Activity and the Inflammation-Induced Expression of Acid-Sensing Ion Channels in Nociceptors","first-page":"1529","author":"Voilley","year":"2001"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25734_bib70","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ddr.21794","article-title":"Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy","volume":"82","author":"Prasher","year":"2021","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.heliyon.2024.e25734_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935676","article-title":"Diclofenac reduces the risk of Alzheimer's disease: a pilot analysis of NSAIDs in two US veteran populations","volume":"13","author":"Stuve","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","article-title":"Neutralizing antibody titres in SARS-CoV-2 infections","volume":"12","author":"Lau","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cellimm.2009.03.007","article-title":"Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells","volume":"258","author":"Bancos","year":"2009","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib74","doi-asserted-by":"crossref","first-page":"8920","DOI":"10.1038\/s41598-021-88356-8","article-title":"Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19","volume":"11","author":"Meinberger","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25734_bib75","article-title":"Risk factors of SARS-CoV-2 infection: global epidemiological study","volume":"2","author":"Barletta","year":"2021","journal-title":"JMIRx Med"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25734_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26092593","article-title":"Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus","volume":"26","author":"Terrier","year":"2021","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25734_bib77","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.heliyon.2024.e25734_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104686","article-title":"Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: non-steroidal anti-inflammatory drugs against COVID-19","volume":"136","author":"Sisakht","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.heliyon.2024.e25734_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104641","article-title":"Structural and functional insights into non-structural proteins of coronaviruses","volume":"150","author":"Rohaim","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.heliyon.2024.e25734_bib80","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1016\/j.csbj.2021.08.029","article-title":"Co-crystallization and structure determination: an effective direction for anti-SARS-CoV-2 drug discovery","volume":"19","author":"Wang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.heliyon.2024.e25734_bib81","series-title":"Structural and Biochemical Characterization of Nsp12-Nsp7-Nsp8 Core Polymerase Complex from COVID-19 Virus","author":"Peng","year":"2020"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14787210.2021.1939683","article-title":"NSAIDs\/nitazoxanide\/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects","volume":"20","author":"Kelleni","year":"2022","journal-title":"Expert Rev. Anti-infect. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25734_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/v13040558","article-title":"In vitro assessment of the antiviral activity of ketotifen, indomethacin and naproxen, alone and in combination, against SARS-CoV-2","volume":"13","author":"Kiani","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e25734_bib84","series-title":"Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Propagation by RNA Oligonucleotides Targeting the PB2 Gene in Combination with Celecoxib","first-page":"1521","author":"Jin","year":"2011"},{"key":"10.1016\/j.heliyon.2024.e25734_bib85","series-title":"Hospitalized COVID-19 Patients Treated with Celecoxib and High Dose Famotidine Adjuvant Therapy Show Significant Clinical Responses","author":"Tomera","year":"2020"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e25734_bib86","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25734_bib87","first-page":"116","article-title":"A review of COVID-19 (Coronavirus Disease-2019) diagnosis, treatments and prevention","volume":"4","author":"Hafeez","year":"2020","journal-title":"Ejmo"},{"key":"10.1016\/j.heliyon.2024.e25734_bib88","article-title":"Current status and future directions of bacteria-based immunotherapy","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib89","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","volume":"100","author":"Classen","year":"2021","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25734_bib90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25734_bib91","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1111\/bcp.15281","article-title":"Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: mechanisms and relevance to infection","volume":"88","author":"Abdel Shaheed","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1078766","article-title":"Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: perspectives in pharmacogenomics","volume":"13","author":"Lai","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12_Supplement","key":"10.1016\/j.heliyon.2024.e25734_bib93","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-2166","article-title":"Ibuprofen induces ferroptosis to potentiate antitumor immunity","volume":"82","author":"Talty","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-020-00266-0","article-title":"The NLRP3 inflammasome: an emerging therapeutic target for chronic pain","volume":"18","author":"Chen","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.heliyon.2024.e25734_bib95","series-title":"Scientific Brief: the Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Patients with COVID-19","author":"Organization","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e25734_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594963","article-title":"Virus infections and host metabolism\u2014can we manage the interactions?","volume":"11","author":"Sumbria","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25734_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572677","article-title":"HIV-1 infection and glucose metabolism reprogramming of T cells: another approach toward functional cure and reservoir eradication","volume":"11","author":"Kang","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25734_bib98","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1128\/JVI.02309-14","article-title":"Dengue virus induces and requires glycolysis for optimal replication","volume":"89","author":"Fontaine","year":"2015","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.immuni.2018.11.017","article-title":"The nucleotide sensor ZBP1 and kinase RIPK3 induce the enzyme IRG1 to promote an antiviral metabolic state in neurons","volume":"50","author":"Daniels","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e25734_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01533","article-title":"Hijacking the supplies: metabolism as a novel facet of virus-host interaction","volume":"10","author":"Mayer","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25734_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002124","article-title":"Divergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolism","volume":"7","author":"Vastag","year":"2011","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib102","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25734_bib103","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1038\/s41598-018-22913-6","article-title":"Association of NF-E2 related factor 2 (Nrf2) and inflammatory cytokines in recent onset type 2 diabetes mellitus","volume":"8","author":"Sireesh","year":"2018","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e25734_bib104","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1080\/10408398.2020.1775546","article-title":"Obesity as a risk factor for COVID-19: an overview","volume":"61","author":"Alberca","year":"2021","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25734_bib105","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/ijo.2011.208","article-title":"Obesity is associated with impaired immune response to influenza vaccination in humans","volume":"36","author":"Sheridan","year":"2012","journal-title":"Int. J. Obes."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e25734_bib106","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.3390\/ijms21103544","article-title":"The role of lipid metabolism in COVID-19 virus infection and as a drug target","volume":"21","author":"Abu-Farha","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25734_bib107","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/nu13031004","article-title":"Ketogenic diet as a preventive and supportive care for COVID-19 patients","volume":"13","author":"Gangitano","year":"2021","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25734_bib108","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.immuni.2022.01.004","article-title":"Control of immunity via nutritional interventions","volume":"55","author":"Collins","year":"2022","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25734_bib109","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s10753-022-01680-7","article-title":"The lactate and the lactate dehydrogenase in inflammatory diseases and major risk factors in COVID-19 patients","volume":"45","author":"Gupta","year":"2022","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25734_bib110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/v14030602","article-title":"Hallmarks of metabolic reprogramming and their role in viral pathogenesis","volume":"14","author":"Allen","year":"2022","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25734_bib111","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/10600280221075362","article-title":"Ibuprofen-associated hypokalemia and metabolic acidosis: systematic literature review","volume":"56","author":"Man","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e25734_bib112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OAEM.S22795","article-title":"The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open access emergency medicine","volume":"3","author":"Hunter","year":"2011","journal-title":"OAEM"},{"key":"10.1016\/j.heliyon.2024.e25734_bib113","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/IJNRD.S121698","article-title":"Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study","volume":"9","author":"Kaewput","year":"2016","journal-title":"Int. J. Nephrol. Renovascular Dis."},{"key":"10.1016\/j.heliyon.2024.e25734_bib114","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00005344-200605001-00007","article-title":"COX-2 and the kidney","volume":"47","author":"Harris","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25734_bib115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.117.09906","article-title":"Cyclooxygenase-2 selectively controls renal blood flow through a novel PPAR\u03b2\/\u03b4-dependent vasodilator pathway","volume":"71","author":"Kirkby","year":"2018","journal-title":"Hypertension"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024017651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024017651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:38:47Z","timestamp":1775457527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024017651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2405844024017651"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25734","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e25734"}}